Skip to main
FBLG
FBLG logo

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics Inc has fortified its clinical capabilities by securing Charles River’s expertise in cGMP manufacturing, allowing for efficient scaling of production and compliance with regulatory standards as it gears up for clinical trial launches. This strategic collaboration enhances FibroBiologics' position in regenerative medicine while expanding its market potential across multiple lucrative therapeutic areas, particularly in advancing its therapy CYWC628 through early-stage trials. Additionally, the completion of the master cell bank for CYWC628 positions the company favorably for future research collaborations and accelerates its path to commercialization, highlighting the innovative potential of fibroblast-based therapies in chronic disease treatment.

Bears say

FibroBiologics faces a challenging financial landscape due to the competitive nature of the cell therapy market and the high costs associated with clinical trials, which may hinder its ability to generate revenue in the near term. Furthermore, the company’s reliance on fibroblast-based therapies to address unmet medical needs, while promising, has yet to yield proven commercial viability or robust clinical results that could attract investors. Additionally, the limited treatment options for conditions like diabetic foot ulcers highlight the urgent need for successful outcomes; however, any delay in achieving regulatory approvals or positive trial results could further adversely impact FibroBiologics’s financial stability and investor confidence.

Fibrobiologics Inc (FBLG) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of Sep 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.